XSJ81

XSJ81 is an orally active anti-cancer agent. XSJ81 significantly inhibits the proliferation of ampullary carcinoma (AC) DPC-X3 cells with an IC50 of 0.655 μM. XSJ81 inhibits the colony formation, arrests cell cycle at the G2/M phase and inhibits the migration in DPC-X3 cells. XSJ81 induces DNA damage and apoptosis in DPC-X3 cells. XSJ81 demonstrates significant anti-tumor efficacy in mice bearing DPC-X3 xenografts. XSJ81 can be used for the study of ampullary carcinoma[1].

Product Specifications

UNSPSC

12352100

Target

Apoptosis; Bcl-2 Family; Topoisomerase

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CC[C@]1(C(OC=C2C(N3CC4=CC5=CC=CC=C5N=C4C3CC21)=O)=O)OC(CNC(NS(=O)(C6=CC=C(C=C6)C)=O)=O)=O

Molecular Formula

C30H28N4O8S

Molecular Weight

604.63

References & Citations

[1]Du L, et al. Antitumor activity of XSJ81, a 20-sulfonated camptothecin derivative, targeting topoisomerase I against ampullary carcinoma. Bioorg Chem. 2025 Aug;163:108780.